<DOC>
	<DOC>NCT01756365</DOC>
	<brief_summary>The study " Autologous cultured corneal epithelium (CECA) for the treatment of unilateral corneal lesions associated with limbal stem cell deficiency" is the first clinical trial of this product manufactured at the LOEX laboratory. The culture of corneal epithelium strives to produce a reconstructed tissue with the therapeutical aim of treatment of unilateral limbal stem cell deficiency (only one eye is affected by the limbal stem cell deficiency). The study is a phase I/phase II study with the goal to evaluate safety and efficacy of the CECA graft for the treatment of human patients suffering from limbal stem cell deficiency.</brief_summary>
	<brief_title>Autologous Cultured Corneal Epithelium (CECA) for the Treatment of Limbal Stem Cell Deficiency</brief_title>
	<detailed_description />
	<criteria>Male and female patients with limbal stem cell deficiency Bilateral limbal stem cell deficiency Unilateral limbal stem cell deficiency with more than 50% of damage to the contralateral eye Pregnancy Breastfeeding Minors known allergy to aprotinine (Trasylol (R)) Hypersensibility to bovine proteins</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>